IMV

InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Potential Synergy With Vilobelimab When Used in Combination with Other Immunomodulators

Retrieved on: 
Mardi, mai 21, 2024
Patient, COVID-19, IMV, Food, FDA, Mortality, Tocilizumab, Conference, American Thoracic Society, MD, Hospice and palliative medicine, JAK, Risk, ATS, Intensive care medicine, Poster, Safety, Therapy, Standard of care, Pharmaceutical industry

InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET.

Key Points: 
  • InflaRx is presenting a poster at the thematic poster session at the ATS conference today from 11:30 AM PT / 2:30 PM ET to 1:15 PM PT / 4:15 PM ET.
  • Tocilizumab, an anti-IL6R antibody, and baricitinib, a JAK inhibitor, are immunomodulators used in some patients as part of the standard of care treatment in this trial.
  • Day 60 all-cause mortality was 16.4% and 49.3%, respectively (HR 0.25; 95% CI:0.09-0.68, p=0.006), a significant relative reduction.
  • We believe this analysis further supports the life-saving potential of vilobelimab in the acute care setting and indicates our continued commitment to these patients.”

BioVaxys Technology Corp. Closes SECOND Tranche of Private Placement

Retrieved on: 
Vendredi, mai 10, 2024
Private, News, IMV, FRA, Person, Unit, Acquisition, Infection, Security (finance)

VANCOUVER, BC, May 10, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 4,301,923 units (the "Units") of the Company at a price of $0.065 per Unit for aggregate gross proceeds of $279,625.00.

Key Points: 
  • VANCOUVER, BC, May 10, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 4,301,923 units (the "Units") of the Company at a price of $0.065 per Unit for aggregate gross proceeds of $279,625.00.
  • Each Unit consists of one common share in the capital of the Company (each, a "Share") and one whole common share purchase warrant (each, a "Warrant"), whereby each Warrant is convertible into one additional Share at an exercise price of $0.15 until May 10, 2026, being the date that is 24 months from the date of issue.
  • All securities issued pursuant to the Second Tranche are subject to a statutory hold period under applicable Canadian securities laws expiring September 11, 2024, being the date that is four months and one day from the date of closing of the Second Tranche.
  • This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States.

BioVaxys Technology Corp. Closes First Tranche of Private Placement

Retrieved on: 
Vendredi, mai 3, 2024
Person, News, Private, Warrant, IMV, Acquisition, Unit, Infection, FRA, Private placement, Security (finance)

VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 5,126,574 units (the "Units") of the Company at a price of $0.065 per Unit for aggregate gross proceeds of $333,227.31.

Key Points: 
  • VANCOUVER, BC, May 3, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (the "Company") is pleased to announce that it has closed the first tranche (the "First Tranche") of its previously announced non-brokered private placement (the "Private Placement") with the issuance of 5,126,574 units (the "Units") of the Company at a price of $0.065 per Unit for aggregate gross proceeds of $333,227.31.
  • In connection with the closing of the First Tranche of the Private Placement, the Company paid cash finder's fees in the aggregate of $6,500 and issued a total of 60,000 finder's warrants (each, a "Finder's Warrant").
  • The Company anticipates closing the second and final tranche (the "Final Tranche") of the Private Placement within the next two weeks.
  • Closing of the Final Tranche is subject to the receipt of all necessary regulatory approvals, including approval of the Canadian Securities Exchange.

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Retrieved on: 
Jeudi, mai 2, 2024
IMV, Ontario Securities Commission, Acquisition, National instrument, Intellectual property, Bank statement, FRA, Music

Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

Key Points: 
  • Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
  • Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
  • The Company anticipates filing the Required Annual Filings and the Required Interim Filings by May 13, 2024.
  • The Company is working with its auditor in order to file the Required Annual Filings and with its accountants in order to file the Required Interim Filings.

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Retrieved on: 
Jeudi, avril 18, 2024
OSC, IMV, Ontario Securities Commission, Acquisition, National instrument, Intellectual property, Bank statement, FRA, Music

Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

Key Points: 
  • Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
  • Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
  • As a result, the Company requested approval from the Ontario Securities Commission for an extension of the MCTO and such extension was granted by the OSC until May 13, 2024.
  • Except as herein disclosed, there are no material changes to the information contained in the Default Announcement.

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Retrieved on: 
Vendredi, avril 5, 2024
IMV, FRA, Acquisition, National instrument, Bank statement, Ontario Securities Commission, Intellectual property

Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.

Key Points: 
  • Under National Instrument 51-102, the Required Annual Filings were required to be made no later than February 28, 2024.
  • Under National Instrument 51-102, the Required Interim Filings were required to be made no later than April 1, 2024.
  • The Company anticipates filing the Required Annual Filings by April 30, 2024.
  • In addition, the Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

BioVaxys Announces Allowance of DPX Formulation Patent for the United States and Filing of Additional International Patent Applications for Phase 1 DPX SurMAGE

Retrieved on: 
Mercredi, avril 3, 2024
Aggression, A9, Immunotherapy, Patent, Infection, Patient, Lung, Neoplasm, Epitope, IMV, FRA, Cancer, Messenger, Bladder cancer, Protein, Trial of the century, CHU, APC, European, Antibody, Immune system, Kidney, Intellectual property, Therapy, Antigen, Peptide, Vaccine

DPX™ is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules.

Key Points: 
  • DPX™ is a proprietary lipid-based delivery platform with no aqueous component that can be formulated with a range of packaged antigens, proteins, peptides, mRNA, or small molecules.
  • Its unique "no release" mechanism of action allows antigen presenting cells (APCs) to be attracted to the injection site, facilitating a robust and sustained immune response.
  • BioVaxys President and Chief Operating Officer Kenneth Kovan stated "Allowance of this important patent in the United States greatly expands the value of our IP and antigen delivery platform with potential partners.
  • We will be reconvening with the study team at CHU de Québec-Université Laval to plan further development."

BIOVAXYS ANNOUNCES PLANNED PRIVATE PLACEMENT

Retrieved on: 
Vendredi, mars 22, 2024
Private, Infection, IMV, FRA, Acquisition, Indian stock exchange, Unit, CAD

VANCOUVER, BC, March 22, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") consisting of up to 15,384,615 units ("Units") at a price of $0.065 per Unit for total gross proceeds of up to CAD$1,000,000, before deducting any offering-related expenses.

Key Points: 
  • VANCOUVER, BC, March 22, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "the Company") announces that it intends to complete a non-brokered private placement (the "Private Placement") consisting of up to 15,384,615 units ("Units") at a price of $0.065 per Unit for total gross proceeds of up to CAD$1,000,000, before deducting any offering-related expenses.
  • Each Unit consists of one common share (a "Common Share") and one whole Common Share purchase warrant (a "Warrant").
  • Closing of the private placement is conditional upon finalizing all contractual documentation and receipt of all applicable regulatory approvals and the policies of the Canadian Securities Exchange ("CSE").
  • All securities issued pursuant to the Private Placement are subject to a statutory hold period of four months and one day from the date of issuance.

BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update

Retrieved on: 
Jeudi, mars 21, 2024
IMV, FRA, Acquisition, National instrument, Bank statement, Ontario Securities Commission, Intellectual property

Under National Instrument 51-102, the Required Annual Filings were required to be made not later than February 28, 2024.

Key Points: 
  • Under National Instrument 51-102, the Required Annual Filings were required to be made not later than February 28, 2024.
  • The Company had expected to file the Required Annual Filings by March 30, 2024, and now anticipates filing the Required Annual Filings by April 30, 2024.
  • Under National Instrument 51-102, the Required Interim Filings are required to be made not later than April 1, 2024.
  • The Company anticipates filing the Required Interim Filings immediately after the filing of the Required Annual Filings.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Vendredi, mars 8, 2024
CFO, Acquisition, Certification, Fortnight, Requirement, News, File, FRA, IAS, Ontario Securities Commission, OSC, DMCL, Documentation, IMV, National Policy, National instrument, IAS 10

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.